|Table of Contents|

Selection of immune-related genes and construction of prognosis model for cholangiocarcinoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 15
Page:
2788-2795
Research Field:
Publishing date:

Info

Title:
Selection of immune-related genes and construction of prognosis model for cholangiocarcinoma
Author(s):
LI Hanqi1; SHI Yu2; WU Shaobo3; TAO Jie1; SUN Hao1; LIU Qingguang1; SUN Liankang1
1.Department of Hepatobiliary Surgery;2.Department of Oncology,the First Affiliated Hospital of Xi'an Jiaotong University,Shaanxi Xi'an 710061,China;3.Health Science Center(HSC) of Xi'an Jiaotong University,Shaanxi Xi'an 710061,China.
Keywords:
immune-related genes; cholangiocarcinoma; prognostic gene model; immune infiltration; drug sensitivity
PACS:
R735.8
DOI:
10.3969/j.issn.1672-4992.2024.15.015
Abstract:
Objective:To construct an immune-related prognostic model of cholangiocarcinoma based on bioinformatics.Methods:First,the RNA sequencing(RNA-seq) data of cholangiocarcinoma(CCA) were downloaded from The Cancer Genome Atlas(TCGA) database and intersected with immune-related genes(IRGs) downloaded from the ImmPort website.Then the "DESeq2" R package was used for differential analysis,and the genes were screened by batch univariate COX and LASSO regression analyses.The obtained 7 genes and clinical information were analyzed using multivariate COX analysis to construct a prognostic model of cholangiocarcinoma.Kaplan-Meier(K-M) survival curves,risk factor correlation analysis and ROC curves as well as nomogram were used for validation.Then we verified the correlations between risk scores and clinical characteristics of CCA patients.Moreover,we also performed functional and pathway enrichment analyses of differentially expressed genes.Finally,we investigated the immune characteristics and drug sensitivity of high- and low-risk groups.Results:Three immune-related genes(GDNF,FGF11,LCN2) were screened out to construct a prognostic model together with "age".The C index value of the model was 0.8.In addition to a poorer prognosis,the degree of immune cell infiltration,immune checkpoint gene expression and proportion of hazardous immune subtypes were larger in high-risk group compared with low-risk group.Moreover,susceptibility of immunotherapy and sensitivity to anti-tumor drugs were relatively poorer in high-risk group.Conclusion:Our immune-related prognostic model can predict the prognosis,immune characteristics and therapy response of patients with cholangiocarcinoma effectively.

References:

［1］VITHAYATHIL M,KHAN SA.Current epidemiology of cholangiocarcinoma in Western countries［J］.Journal of Hepatology,2022,77(6):1690-1698.
［2］ZHANG ZJ,HUANG YP,LIU ZT,et al.Identification of immune related gene signature for predicting prognosis of cholangiocarcinoma patients［J］.Frontiers in Immunology,2023,14:1028404.
［3］MERTERS J,LAMARCA A.Integrating cytotoxic,targeted and immune therapies for cholangiocarcinoma［J］.Journal of Hepatology,2023,78(3):652-657.
［4］RIZVI S,KHAN SA,HALLEMEIER CL,et al.Cholangiocarcinoma-evolving concepts and therapeutic strategies［J］.Nature Reviews Clinical Oncology,2018,15(2):95-111.
［5］LI YS,LI FF,JIANG F,et al.A mini-review for cancer immunotherapy:Molecular understanding of PD-1/PD-L1 pathway & translational blockade of immune checkpoints［J］.International Journal of Molecular Sciences,2016,17(7):1151.
［6］SUN BY,ZHOU C,GUAN RY,et al.Dissecting intra-tumoral changes following immune checkpoint blockades in intrahepatic cholangiocarcinoma via single-cell analysis［J］.Frontiers in Immunology,2022,13:871769.
［7］HU FF,LIU CJ,LIU LL,et al.Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response［J］.Briefings in Bioinformatics,2021,22(3):bbaa176.
［8］XU WX,ZHANG J,HUA YT,et al.An integrative pan-cancer analysis revealing LCN2 as an oncogenic immune protein in tumor microenvironment［J］.Frontiers in Oncology,2020,10:605097.
［9］TAGAWA ST,BALAR AV,PETRYLAK DP.TROPHY-U-01:A phase Ⅱ open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors［J］.Journal of Clinical Oncology,2021,39(22):2474-2485.
［10］CHAROENTONG P,FINOTELLO F,ANGELOVA M,et al.Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade［J］.Cell Reports,2017,18(1):248-262.
［11］MARIATHASAN S,TURLEY SJ,NICKLES D,et al.TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells［J］.Nature,2018,554(7693):544-548.
［12］NAKAMURA H,ARAI Y,TOTOKI Y,et al.Genomic spectra of biliary tract cancer［J］.Nature Genetics,2015,47(9):1003-1010.
［13］NEPAL C,ZHU B,O'ROURKE CJ,et al.Integrative molecular characterisation of gallbladder cancer reveals micro-environment-associated subtypes［J］.Journal of Hepatology,2021,74(5):1132-1144.
［14］LOPEZ-SOTO A,GONZALEZ S,SMYTH MJ,et al.Control of metastasis by NK cells［J］.Cancer Cell,2017,32(2):135-154.
［15］LIU SZ,GALAT V,GALAT Y,et al.NK cell-based cancer immunotherapy:From basic biology to clinical development［J］.Hematol Oncol,2021,14(1):7.
［16］THORSSON V,GIBBS DL,BROWN SD,et al.The immune landscape of cancer［J］.Immunity,2018,48(4):812-830.e14.
［17］NI B,HE X,ZHANG YQ,et al.Tumor-associated macrophage-derived GDNF promotes gastric cancer liver metastasis via a GFRA1-modulated autophagy flux［J］.Cell Oncol(Dordr),2023,46(2):315-330.
［18］WU XW,LI MJ,LI Y,et al.Fibroblast growth factor 11(FGF11) promotes non-small cell lung cancer(NSCLC) progression by regulating hypoxia signaling pathway［J］.Transl Med,2021,19(1):353.
［19］JABERI SA,COHEN A,D'SOUZA C,et al.Lipocalin-2:Structure,function,distribution and role in metabolic disorders［J］.Biomed Pharmacother,2021,142:112002.

Memo

Memo:
National Natural Science Foundation of China(No.82303663);国国家自然科学基金（编号：82303663）；陕西省自然科学基金（编号：2022JQ-846）；西安交通大学第一附属医院院基金（编号：2021QN-01，2022QN-15）；西安交通大学科研基金（编号：xzy012022103）
Last Update: 2024-06-28